Stock Analysis:ProMetic Life Sciences (TSE:PLI) Stock Target Has Just Been Increased
In recent note issued to investors and clients by RBC Capital Markets on Wednesday morning, ProMetic Life Sciences (TSE:PLI) had its TP increased to $4.50. The firm currently has a solid “Outperform” rating on shares.
From a total of 6 analysts covering ProMetic Life Sciences Inc. (TSE:PLI) stock, 6 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that 100% of the ratings are positive. The highest target price is $7.48 while the lowest target price is $2.62. The mean of all analyst targets is $3.94 with a 11.25% above today’s ($3.2) stock price. ProMetic Life Sciences Inc. was the topic of 5 analyst reports since August 10, 2015 according to the firm StockzIntelligence Inc. Paradigm Research reinitiated shares on September 28 with “Buy” rating.
Approximately 1.72 million shares of stock traded hands. ProMetic Life Sciences Inc. (TSE:PLI) has risen 26.61% since April 29, 2015 and is uptrending. It has outperformed by 26.81% the S&P500.
ProMetic Life Sciences Inc. is a Canada biopharmaceutical company. The company has a market cap of $1.86 billion. The Firm offers solutions in bioseparations, plasma-derived therapeutics and small-molecule drug development. It currently has negative earnings. ProMetic offers its technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens.